NCT04958226 - A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 15, 2021

Primary Completion Date

February 6, 2023

Study Completion Date

February 15, 2023

Conditions

Solid Tumour

Interventions

DRUG

Capivasertib

Capivasertib (tablet) will be given as an intermittent schedule (4 days on/3 days off) from Cycle 1 Day 2 until discontinuation. Capivasertib will be administrated in both Part A and Part B.

DRUG

Midazolam

Single doses of midazolam (syrup, 1 mg) will be given on cycle 1 Days 1, 8, and 12.

Trial Locations (5)

15232

Research Site, Pittsburgh

27710

Research Site, Durham

44106

Research Site, Cleveland

75251

Research Site, Dallas

80045

Research Site, Aurora